HC Wainwright reaffirmed their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research report sent to investors on Tuesday morning, BenzingaRatingsTable reports. They currently have a $37.00 target price on the stock, up from their prior target price of $36.00.

Other equities research analysts have also issued reports about the stock. Canaccord Genuity reissued a buy rating and set a $22.00 target price on shares of Karyopharm Therapeutics in a report on Thursday, December 12th. Robert W. Baird set a $25.00 target price on shares of Karyopharm Therapeutics and gave the stock a buy rating in a report on Tuesday, September 24th. JPMorgan Chase & Co. boosted their target price on shares of Karyopharm Therapeutics from $23.00 to $27.00 and gave the stock an overweight rating in a report on Thursday, January 9th. Zacks Investment Research raised shares of Karyopharm Therapeutics from a hold rating to a strong-buy rating and set a $21.00 target price on the stock in a report on Tuesday. Finally, Bank of America upgraded shares of Karyopharm Therapeutics from an underperform rating to a neutral rating in a research report on Friday, January 3rd. Two analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $22.14.

KPTI traded up $0.48 during trading on Tuesday, reaching $18.36. 132,599 shares of the company’s stock were exchanged, compared to its average volume of 1,132,005. Karyopharm Therapeutics has a one year low of $3.92 and a one year high of $20.09. The company has a current ratio of 7.16, a quick ratio of 7.16 and a debt-to-equity ratio of 2.03. The stock has a market capitalization of $1.12 billion, a PE ratio of -5.82 and a beta of 2.59. The firm has a fifty day moving average price of $17.89 and a two-hundred day moving average price of $12.15.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Monday, November 4th. The company reported ($0.67) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.17. Karyopharm Therapeutics had a negative net margin of 909.24% and a negative return on equity of 187.25%. The firm had revenue of $13.15 million for the quarter, compared to analyst estimates of $1.61 million. Sell-side analysts expect that Karyopharm Therapeutics will post -3.13 earnings per share for the current year.

In other news, CEO Michael Kauffman sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $14.17, for a total value of $283,400.00. Also, insider Sharon Shacham sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $12.00, for a total transaction of $120,000.00. Following the completion of the transaction, the insider now owns 741,134 shares in the company, valued at approximately $8,893,608. The disclosure for this sale can be found here. Insiders sold a total of 135,463 shares of company stock worth $2,182,510 in the last 90 days. Corporate insiders own 11.63% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in shares of Karyopharm Therapeutics by 8.3% during the 2nd quarter. BlackRock Inc. now owns 4,526,508 shares of the company’s stock valued at $27,112,000 after acquiring an additional 347,700 shares during the period. State Street Corp raised its holdings in Karyopharm Therapeutics by 181.2% during the third quarter. State Street Corp now owns 3,148,516 shares of the company’s stock worth $30,289,000 after buying an additional 2,028,790 shares during the last quarter. Orbimed Advisors LLC acquired a new position in Karyopharm Therapeutics during the second quarter worth $18,859,000. Vanguard Group Inc. raised its holdings in Karyopharm Therapeutics by 14.1% during the second quarter. Vanguard Group Inc. now owns 2,983,862 shares of the company’s stock worth $17,874,000 after buying an additional 369,590 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in Karyopharm Therapeutics during the second quarter worth $15,552,000. Institutional investors own 93.14% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).

Further Reading: Risk Tolerance

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.